Cargando…

Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm

INTRODUCTION: It is unclear whether adding basal insulin or enhancing incretin signaling with a glucagon-like peptide-1 receptor agonist (GLP-1RA) is more effective as an up-titration strategy after dipeptidyl peptidase-4 inhibitor (DPP-4i)-based oral antidiabetic drug (OAD) therapy. GLP-1RAs can be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyagi, Masahiko, Uchino, Hiroshi, Kumashiro, Naoki, Higa, Mariko, Shin, Koki, Sasamoto, Makiko, Kitazato, Hiroji, Tamaki, Motoyuki, Matsuhisa, Munehide, Hirose, Takahisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167274/ https://www.ncbi.nlm.nih.gov/pubmed/30121725 http://dx.doi.org/10.1007/s13300-018-0486-1

Ejemplares similares

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
por: Shigiyama, Fumika, et al.
Publicado: (2017)

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
por: Shigiyama, Fumika, et al.
Publicado: (2016)

Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial
por: Iga, Ryo, et al.
Publicado: (2017)

Basal insulin titration by the app
por: Vangoitsenhoven, Roman, et al.
Publicado: (2023)

Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium–glucose cotransporter 2 inhibitor: A randomized, open‐label, prospective study
por: Kanazawa, Ken, et al.
Publicado: (2019)

Advanced glycation end‐products are a risk for muscle weakness in Japanese patients with type 1 diabetes
por: Mori, Hiroyasu, et al.
Publicado: (2016)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

Successful Treatment of Amiodarone-induced Thyrotoxicosis Type 1 in Combination with Methimazole and Potassium Iodide in a Patient with Hashimoto's Thyroiditis
por: Katoh, Daisuke, et al.
Publicado: (2019)

Aldosterone-to-Renin Ratio Is Associated with Diabetic Nephropathy in Type 2 Diabetic Patients: A Single-Center Retrospective Study
por: Higa, Mariko, et al.
Publicado: (2022)

Acute suppurative thyroiditis in infected thyroid cyst in an adult patient under hemodialysis
por: Igarashi, Hiroyuki, et al.
Publicado: (2017)

Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes
por: Valentine, Virginia, et al.
Publicado: (2017)

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
por: Fuchigami, Ayako, et al.
Publicado: (2020)

The importance of the initial period of basal insulin titration in people with diabetes
por: Khunti, Kamlesh, et al.
Publicado: (2020)

A Case of Acute-Onset Type 1 Diabetes Mellitus with Diabetic Ketoacidosis Triggered by COVID-19
por: Zenri, Mariko, et al.
Publicado: (2023)

A comparison of meal tolerance test and oral glucose tolerance test for predicting insulin therapy in patients with gestational diabetes
por: Hijikata, Mai, et al.
Publicado: (2021)

New risk factors of severe hypoglycemia
por: Matsuhisa, Munehide, et al.
Publicado: (2018)

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
por: Brown, Dominique Xavier, et al.
Publicado: (2012)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study
por: Shigiyama, Fumika, et al.
Publicado: (2018)

Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well‐controlled type 2 diabetes: A 24‐week randomized controlled trial
por: Ando, Yasuyo, et al.
Publicado: (2021)

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
por: Dicembrini, Ilaria, et al.
Publicado: (2011)

Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2015)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

Combination treatment of db/db mice with exendin‐4 and gastrin preserves β‐cell mass by stimulating β‐cell growth and differentiation
por: Tamaki, Motoyuki, et al.
Publicado: (2010)

Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan
por: Hisanaga, Kaori, et al.
Publicado: (2021)

Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist
por: Patel, Dhiren, et al.
Publicado: (2019)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Dihydromyricetin Enhances Exercise-Induced GLP-1 Elevation through Stimulating cAMP and Inhibiting DPP-4
por: Wu, Luting, et al.
Publicado: (2022)

Inhibition of DPP-IV Activity and Stimulation of GLP-1 Release by Gastrointestinally Digested Black Soldier Fly Prepupae
por: Luparelli, Anna Valentina, et al.
Publicado: (2023)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
por: Stenlid, Rasmus, et al.
Publicado: (2023)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

Giant Cavernous Hemangioma of the Adrenal Gland in an Elderly Patient
por: Hashimoto, Ayana, et al.
Publicado: (2017)

Basal insulin requirement in patients with type 1 diabetes depends on the age and body mass index
por: Mitsui, Yukari, et al.
Publicado: (2021)

Retraction Note: therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2016)

Influence of Diet and Gender on Plasma DPP4 Activity and GLP-1 in Patients with Metabolic Syndrome: An Experimental Pilot Study
por: Pérez-Durillo, Francisco Tomás, et al.
Publicado: (2018)

DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction
por: Kim, Seung Jung, et al.
Publicado: (2019)

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes
por: Han, Eugene, et al.
Publicado: (2016)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
por: Gilbert, Matthew P., et al.
Publicado: (2020)

Targeting cellular senescence prevents glucocorticoid-induced bone loss through modulation of the DPP4-GLP-1 axis
por: Wang, Tiantian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lv3r4m7p0sbjjkebjvhqdjfrt2